Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;8(1):100751.
doi: 10.1016/j.esmoop.2022.100751. Epub 2023 Jan 16.

Emerging targets for cancer treatment: S100A9/RAGE

M Valiente  1 , J M Sepúlveda  2 , A Pérez  3
Affiliations
Review

Emerging targets for cancer treatment: S100A9/RAGE

M Valiente et al. ESMO Open. 2023 Feb.

Abstract

Developing better treatments that work for the majority of patients with brain metastasis (BM) is highly necessary. Complementarily, avoiding those therapeutic procedures that will not benefit a specific patient is also very relevant. In general, existing therapies for patients with BM could be improved in terms of molecular stratification and therapeutic efficacy. By questioning the benefit of whole brain radiotherapy as provided nowadays and the lack of biomarkers detecting radioresistance, we identified S100A9 and receptor for advanced glycation end-products (RAGE) as a liquid biopsy biomarker and a potential target for a radiosensitizer, respectively. Both of them are being clinically tested as part of the first comprehensive molecular strategy to personalized radiotherapy in BM.

Keywords: JunB; NF-κB; RAGE; S100A9; brain metastasis; clinical trial with RAGE inhibitor; observational prospective study; radioresistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the prospective observational study in patients with brain metastases sponsored by RENACER. CNS, central nervous system; RT, radiotherapy; SRS, stereotactic radiosurgery; WBRT, whole brain radiotherapy.
Figure 2
Figure 2
Flow chart with the design of the trial CAN-201: a phase I/II open-label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma. ECOG, Eastern Cooperative Oncology Group.
Figure 3
Figure 3
Flow chart with the design of a clinical trial with azeliragon in combination with radiotherapy in patients with brain metastases from non-small-cell lung cancer, breast cancer or melanoma.
See this image and copyright information in PMC

References

    1. Monteiro C., Miarka L., Perea-García M., et al. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nat Med. 2022;28:752–765. - PMC - PubMed
    1. Orgaz J.L., Crosas-Molist E., Sadok A., et al. Myosin II reactivation and cytoskeletal remodeling as a hallmark and a vulnerability in melanoma therapy resistance. Cancer Cell. 2020;37:85–103.e9. - PMC - PubMed
    1. Alexander B.M., Brown P.D., Ahluwalia M.S., et al. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018;19:e33–e42. - PubMed
    1. Al-Robaiy S., Weber B., Simm A., et al. The receptor for advanced glycation end-products supports lung tissue biomechanics. Am J Physiol Lung Cell Mol Physiol. 2013;305:L491–L500. - PubMed
    1. El-Far A.H., Sroga G., Jaouni S.K.A., Mousa S.A. Role and mechanisms of RAGE-ligand complexes and RAGE-inhibitors in cancer progression. Int J Mol Sci. 2020;21:3613. - PMC - PubMed